scholarly journals A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

1997 ◽  
Vol 337 (11) ◽  
pp. 725-733 ◽  
Author(s):  
Scott M. Hammer ◽  
Kathleen E. Squires ◽  
Michael D. Hughes ◽  
Janet M. Grimes ◽  
Lisa M. Demeter ◽  
...  
1993 ◽  
Vol 148 (5) ◽  
pp. 1292-1297 ◽  
Author(s):  
Brenda E. Jones ◽  
Summer M. M. Young ◽  
Diana Antoniskis ◽  
Paul T. Davidson ◽  
Françoise Kramer ◽  
...  

1996 ◽  
Vol 40 (11) ◽  
pp. 2664-2668 ◽  
Author(s):  
A M Been-Tiktak ◽  
I Williams ◽  
H M Vrehen ◽  
J Richens ◽  
D Aldam ◽  
...  

Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4+ cell counts of between 200 and 750 cells per mm3. Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.


1998 ◽  
Vol 26 (1) ◽  
pp. 85-90 ◽  
Author(s):  
Ramón A. Torres ◽  
James D. Neaton ◽  
Deborah N. Wentworth ◽  
Michael R. Barr ◽  
Donald Abrams ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document